Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Inclusion Criteria

• •Signed written informed consent
• •Histologically confirmed primary invasive adenocarcinoma of the breast with the size of the primary tumor being at least 1 cm on imaging by either mammography, ultrasound or breast magnetic resonance imaging (MRI)
• •Negative human epidermal growth factor receptor 2 (HER-2)/neu- disease defined as patients with fluorescence in situ hybridization (FISH) ratio \< 2.0 or \< 6.0 HER2 gene copies per nucleus, and IHC staining scores of 0, 1+, or 2+
• •No treatment for current primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, immunotherapy, investigational therapy or surgery; previous treatment for breast and/or ovarian cancer with chemotherapy, endocrine therapy, surgery and radiation are allowed if \>= 3 years prior to current diagnosis and there is no clinical evidence of metastatic disease
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• •Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of \> 50%
• •Absolute neutrophil count (ANC) \>= 1,500/uL
• •Platelets \>= 100,000/uL
• •Hemoglobin (Hgb) \>= 9 g/dL
• •Creatinine clearance \> 50 ml/min
• •Total bilirubin =\< 1.5 X upper limit of normal (ULN)
• •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 X ULN
• •Negative serum or urine pregnancy test for women within 7 days of receiving the first dose of the study medication for women of childbearing potential; women will be considered not of childbearing potential and exempt from pregnancy testing if they are either a) older than 50 and amenorrheic for at least 12 consecutive months following cessation of all exogenous hormonal treatments, or b) have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
• •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product; men on study also must be using contraception
• •Identified deleterious mutation in BRCA 1 or 2 genes (this does not include variants of uncertain significance)
• •Eligible to receive standard of care chemotherapy and/or surgery based upon standard practices or institutional guidelines